ContraFect Corp (CFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH274012D
- Pages: 57
- October 2018
- Total Views:1154
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
ContraFect Corp (ContraFect) is a clinical stage biotechnology company that discovers and develops therapeutic protein and antibody products. The company develops products using lysin and monoclonal antibody platforms for the treatment of life threatening, drug-resistant infectious diseases. Its lead product candidates include CF-301, a recombinant bacteriophage derived lysin intended for the treatment of staphylococcus aureus bloodstream infections and offers CF-404, a combination of human monoclonal antibodies intended for the treatment of seasonal and pandemic influenza infections. The company's pipeline portfolio consists other lysin candidates in preclinical stage. ContraFect is headquartered in Yonkers, New York, the US.
ContraFect Corp (CFRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraFect Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ContraFect Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ContraFect Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ContraFect Raises USD 12 Million In Venture Financing 11
ContraFect Raises USD 9.5 Million In Venture Financing 12
Partnerships 13
ContraFect Enters into Research Agreement with Rockefeller University 13
ContraFect Enters into Research Agreement with National Institute for Viral Disease Control and Prevention for CF-404 14
Licensing Agreements 15
ContraFect Enters Into Licensing Agreement With Trellis 15
ContraFect Amends Licensing Agreement With Trellis 16
Equity Offering 17
ContraFect Prices Public Offering of Shares for USD10 Million 17
ContraFect Raises USD40 Million in Public Offering of Shares and Warrants 19
ContraFect to Raise Up to USD4.9 Million in Public Offering of Shares 21
ContraFect Raises Funds through Public Offering of Shares and Warrants 22
ContraFect Raises USD35 Million in Public Offering of Shares 23
ContraFect Raises USD20 Million in Private Placement Shares and Warrants 24
ContraFect Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD41 Million 25
ContraFect Corp-Key Competitors 27
ContraFect Corp-Key Employees 28
ContraFect Corp-Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: Contrafect announces second quarter 2018 financial results 30
May 10, 2018: ContraFect Announces First Quarter 2018 Financial Results 31
Mar 15, 2018: ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 32
Nov 09, 2017: ContraFect Announces Third Quarter 2017 Financial Results 34
Aug 09, 2017: ContraFect Announces Second Quarter 2017 Financial Results 35
May 08, 2017: ContraFect Announces First Quarter 2017 Financial Results 36
Mar 15, 2017: ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 37
Corporate Communications 39
Oct 05, 2017: ContraFect Appoints Lisa Ricciardi as Chief Operating Officer 39
Feb 15, 2017: Lisa Ricciardi to Join Board of Directors 40
Product News 41
11/15/2017: ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference 41
11/10/2017: ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference 42
10/17/2017: ContraFect to Present at the 4th Annual Re-entering Antibacterial Discovery and Development Summit 43
09/29/2017: ContraFect to Present New Data on CF-301 at ID Week 2017 44
09/11/2017: ContraFect to Present at 2017 World Antimicrobial Resistance Congress 45
04/11/2018: ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases 46
03/30/2017: ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program 48
Clinical Trials 49
Mar 14, 2018: ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference 49
Jan 03, 2018: ContraFect to Present at 10th Annual Biotech Showcase 50
Sep 28, 2017: ContraFect to Present at The MicroCap Conference 51
Sep 13, 2017: ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference 52
Jun 01, 2017: ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017 53
May 25, 2017: ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia 54
Apr 19, 2017: ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease 55
Jan 06, 2017: ContraFect Provides Update On Its Clinical Development Timeline For CF-301 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
List Of Figure
List of Figures
ContraFect Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraFect Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
ContraFect Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraFect Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraFect Corp, Deals By Therapy Area, 2012 to YTD 2018 9
ContraFect Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ContraFect Raises USD 12 Million In Venture Financing 11
ContraFect Raises USD 9.5 Million In Venture Financing 12
ContraFect Enters into Research Agreement with Rockefeller University 13
ContraFect Enters into Research Agreement with National Institute for Viral Disease Control and Prevention for CF-404 14
ContraFect Enters Into Licensing Agreement With Trellis 15
ContraFect Amends Licensing Agreement With Trellis 16
ContraFect Prices Public Offering of Shares for USD10 Million 17
ContraFect Raises USD40 Million in Public Offering of Shares and Warrants 19
ContraFect to Raise Up to USD4.9 Million in Public Offering of Shares 21
ContraFect Raises Funds through Public Offering of Shares and Warrants 22
ContraFect Raises USD35 Million in Public Offering of Shares 23
ContraFect Raises USD20 Million in Private Placement Shares and Warrants 24
ContraFect Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD41 Million 25
ContraFect Corp, Key Competitors 27
ContraFect Corp, Key Employees 28
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
ContraFect Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
ContraFect Corp (ContraFect) is a clinical stage biotechnology company that discovers and develops therapeutic protein and antibody products. The company develops products using lysin and monoclonal antibody platforms for the treatment of life threatening, drug-resistant infectious diseases. Its lead product candidates include CF-301, a recombinant bacteriophage derived lysin intended for the treatment of staphylococcus aureus bloodstream infections and offers CF-404, a combination of human monoclonal antibodies intended for the treatment of seasonal and pandemic influenza infections. The company's pipeline portfolio consists other lysin candidates in preclinical stage. ContraFect is headquartered in Yonkers, New York, the US.
ContraFect Corp (CFRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraFect Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ContraFect Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ContraFect Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ContraFect Raises USD 12 Million In Venture Financing 11
ContraFect Raises USD 9.5 Million In Venture Financing 12
Partnerships 13
ContraFect Enters into Research Agreement with Rockefeller University 13
ContraFect Enters into Research Agreement with National Institute for Viral Disease Control and Prevention for CF-404 14
Licensing Agreements 15
ContraFect Enters Into Licensing Agreement With Trellis 15
ContraFect Amends Licensing Agreement With Trellis 16
Equity Offering 17
ContraFect Prices Public Offering of Shares for USD10 Million 17
ContraFect Raises USD40 Million in Public Offering of Shares and Warrants 19
ContraFect to Raise Up to USD4.9 Million in Public Offering of Shares 21
ContraFect Raises Funds through Public Offering of Shares and Warrants 22
ContraFect Raises USD35 Million in Public Offering of Shares 23
ContraFect Raises USD20 Million in Private Placement Shares and Warrants 24
ContraFect Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD41 Million 25
ContraFect Corp-Key Competitors 27
ContraFect Corp-Key Employees 28
ContraFect Corp-Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: Contrafect announces second quarter 2018 financial results 30
May 10, 2018: ContraFect Announces First Quarter 2018 Financial Results 31
Mar 15, 2018: ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 32
Nov 09, 2017: ContraFect Announces Third Quarter 2017 Financial Results 34
Aug 09, 2017: ContraFect Announces Second Quarter 2017 Financial Results 35
May 08, 2017: ContraFect Announces First Quarter 2017 Financial Results 36
Mar 15, 2017: ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 37
Corporate Communications 39
Oct 05, 2017: ContraFect Appoints Lisa Ricciardi as Chief Operating Officer 39
Feb 15, 2017: Lisa Ricciardi to Join Board of Directors 40
Product News 41
11/15/2017: ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference 41
11/10/2017: ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference 42
10/17/2017: ContraFect to Present at the 4th Annual Re-entering Antibacterial Discovery and Development Summit 43
09/29/2017: ContraFect to Present New Data on CF-301 at ID Week 2017 44
09/11/2017: ContraFect to Present at 2017 World Antimicrobial Resistance Congress 45
04/11/2018: ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases 46
03/30/2017: ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program 48
Clinical Trials 49
Mar 14, 2018: ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference 49
Jan 03, 2018: ContraFect to Present at 10th Annual Biotech Showcase 50
Sep 28, 2017: ContraFect to Present at The MicroCap Conference 51
Sep 13, 2017: ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference 52
Jun 01, 2017: ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017 53
May 25, 2017: ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia 54
Apr 19, 2017: ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease 55
Jan 06, 2017: ContraFect Provides Update On Its Clinical Development Timeline For CF-301 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
List Of Figure
List of Figures
ContraFect Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraFect Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
ContraFect Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraFect Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraFect Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraFect Corp, Deals By Therapy Area, 2012 to YTD 2018 9
ContraFect Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ContraFect Raises USD 12 Million In Venture Financing 11
ContraFect Raises USD 9.5 Million In Venture Financing 12
ContraFect Enters into Research Agreement with Rockefeller University 13
ContraFect Enters into Research Agreement with National Institute for Viral Disease Control and Prevention for CF-404 14
ContraFect Enters Into Licensing Agreement With Trellis 15
ContraFect Amends Licensing Agreement With Trellis 16
ContraFect Prices Public Offering of Shares for USD10 Million 17
ContraFect Raises USD40 Million in Public Offering of Shares and Warrants 19
ContraFect to Raise Up to USD4.9 Million in Public Offering of Shares 21
ContraFect Raises Funds through Public Offering of Shares and Warrants 22
ContraFect Raises USD35 Million in Public Offering of Shares 23
ContraFect Raises USD20 Million in Private Placement Shares and Warrants 24
ContraFect Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD41 Million 25
ContraFect Corp, Key Competitors 27
ContraFect Corp, Key Employees 28
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
ContraFect Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
March 2021
Page 140 | November 2020
Page 99 | July 2020
Page 75 | July 2020
Page 114 | May 2020